Literature DB >> 12906330

Behavior of decomposition of rifampicin in the presence of isoniazid in the pH range 1-3.

R Sankar1, Nishi Sharda, Saranjit Singh.   

Abstract

The extent of decomposition of rifampicin in the presence of isoniazid was determined in the pH range 1-3 at 37 degrees C in 50 min, the mean stomach residence time. With increase in pH, the degradation initially increased from pH 1 to 2 and then decreased, resulting in a bell-shaped pH-decomposition profile. This showed that rifampicin degraded in the presence of isoniazid to a higher extent at pH 2, the maximum pH in the fasting condition, under which antituberculosis fixed-dose combination (FDC) products are administered. At this pH and in 50 min, rifampicin decomposed by approximately 34%, while the fall of isoniazid was 10%. The extent of decomposition for the two drugs was also determined in marketed formulations, and the values ranged between 13-35% and 4-11%, respectively. The extents of decomposition at stomach residence times of 15 min and 3 h were 11.94% and 62.57%, respectively, for rifampicin and 4.78% and 11.12%, respectively, for isoniazid. The results show that quite an extensive loss of rifampicin and isoniazid can occur as a result of interaction between them in fasting pH conditions. This emphasizes that antituberculosis FDC formulations, which contain both drugs, should be designed in a manner that the interaction of the two drugs is prevented when the formulations are administered on an empty stomach.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12906330     DOI: 10.1081/ddc-120021772

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  2 in total

Review 1.  Tuberculosis chemotherapy: current drug delivery approaches.

Authors:  Lisa Claire du Toit; Viness Pillay; Michael Paul Danckwerts
Journal:  Respir Res       Date:  2006-09-19

Review 2.  Multicomponent crystals of anti-tuberculosis drugs: a mini-review.

Authors:  Eustina Batisai
Journal:  RSC Adv       Date:  2020-10-07       Impact factor: 4.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.